Measuring Thyroglobulin Concentrations in Patients with Differentiated Thyroid Carcinoma

Open access

Measuring Thyroglobulin Concentrations in Patients with Differentiated Thyroid Carcinoma

Thyroid carcinomas are the most common malignant endocrine tumors. Thyroglobulin (Tg), a specific thyroid protein, is the most important tumor marker in thyroid oncology. After total thyroidectomy or radioiodine therapy, detectable or increasing serum Tg levels in patients with differentiated thyroid carcinoma indicate persistence of active thyroid tissue or cancer recurrence. Serum Tg concentration primarily reflects three variables: the mass of differentiated thyroid tissue present; the degree of thyrotropin receptor stimulation and the intrinsic ability of the tumor to synthesize and secrete Tg. Measurement of serum Tg by current immunometric (IMA) and radioimmunological (RIA) assays encounters some methodological problems which can diminish its clinical importance. Discrepancy between the results for Tg using different methods may be caused by: different reference materials, specific properties of the primary and secondary antibodies for antigenic determinants on Tg and diverse binding affinities of these epitopes, together with interference by serum factors (usually antibodies to Tg (TgAb)) with the primary and secondary Tg antibodies from the diagnostic set. In the presence of endogenous TgAb, Tg values measured by immunoradiometric assay (IRMA) and similar assays are usually lower than the real concentrations, while in RIA apparently lower or higher results can be obtained. Falsely low values may lead to delay in necessary treatment, while an inappropriately high Tg value can cause patient anxiety and unnecessary scans. Despite current methodological limitations, serum Tg measurement is a useful test for determining worsening disease and monitoring the effects of therapy in patients who have undergone surgery for differentiated thyroid carcinoma.

Davies I, Welch HG. Increasing incidence of thyroid cancer in the United States 1973-2002. JAMA 2006; 293: 2164-7.

Kovacs GL, Gonda G, Vadasz G, Ludmany G, Uhrin E, Gorombey K, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005; 15: 152-7.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce. Thyroid 2006; 16: 109-42.

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.

Ito Y, Uruno T, Nakano K, Fukushima M, Kihara M, Higashiyama T, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of thyroid. Thyroid 2003; 13: 381-7.

Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion. (First of two parts). N Engl J Med 1979; 301: 239-49.

Sinadinović J, Cvejić D, Savin S, Jancić-Zuguricas M, Mićić JV. Altered terminal glycosylation of thyroglobulin in papillary thyroid carcinoma. Exp Clin Endocrinol 1992; 100: 124-8.

Sinadinović J, Cvejić D, Savin S, Mićić JV, Janćić-Zguricas M. Enhanced acid protease activity of lysosomes from papillary thyroid carcinoma. Cancer 1989; 63: 1179-82.

Okosieme OE, Evans C, Moss L, Parkes AB, Premawardhana LD, Lazarus JH. Thyroglobulin antibody in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin Chem 2005; 51: 729-34.

Estienne B, McIntosh RS, Ruf J, Asghar MS, Watson PF, Carayon P, et al. Comparative mapping of cloned human and murine antithyroglobulin antibodies: recognition of human antibodies of an immunodominant region. Thyroid 1998; 8: 643-8.

Mariotti S, Barbesino G, Caturegli P, Marinó M, Manetti L, Pacini F, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab 1995; 80: 468-72.

Erali M, Bigelow RB, Meikle AW. ELISA for thyroglobulin in serum. Recovery studies to evaluate auto-antibody interference and reliability of thyroglobulin values. Clin Chem 1996; 42: 766-70.

Trbojević B, Nedeljković-Beleslin B. Importance of hormones and proteins determination in the material obtained by fine-needle aspiration. Journal of Medical Biochemistry 2010; 29: 237-44.

Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem 1996; 42: 183-7.

Spencer CA, LoPresti JS. Technology insight: measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Endocrinology and Metabolism 2008; 4: 223-33.

Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastasis of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck limph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006; 91: 1364-9.

Cunha N, Rodrigues F, Curado F, Ilheu O, Cruz C, Naidenov P, et al. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol 2007; 157: 101-7.

Hocevar M, Auersperg M. Role of serum thyroglobulin in the preoperative evaluation of follicular thyroid tumours. Eur J Surg Oncol 1998; 24: 553-7.

Sharma AK, Sarda AK, Chattopadhyay TK, Kapur MM. The role of estimation of the ratio of preoperative serum thyroglobulin to the thyroid mass in predicting the behaviour of well differentiated thyroid cancers. J Postgrad Med 1996; 42: 39-42.

Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995; 24: 841-63.

Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol (OxF) 2007; 67: 547-51.

Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997; 23: 208-10.

Van Wyngaarden K, McDougall IR. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 1997; 7: 343-46.

Grünwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. Prognostic Value of Thyroglobulin after Thyroidectomy before Ablative Radioiodine Therapy in Thyroid Cancer. J Nucl Med 1996; 37: 1962-4.

Herle van AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (second of two parts). N Engl J Med 1979; 301: 307-14.

Sinadinović J, Mićić JV, Krainčanić M, Kostić G, Savin S. Korelacija između nivoa Tg u cirkulaciji, funkcije tireoideje i njene strukture. Radiol lugoslav 1982; 16: 239-43.

Lin JD, Huang MJ, Hsu BR, Chao TC, Hsueh C, Liu FH, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002; 80: 45-51.

Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999; 26: 1448-52.

Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 1440-5.

Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1433-41.

Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive values of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88: 1107-11.

David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005; 15: 158-64.

Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85.

Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999; 9: 435-41.

Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3668-73.

Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio F, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf) 2003; 58: 556-61.

Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90: 5566-75.

Black EG, Hoffenberg R. Should one measure serum thyroglobulin in the presence of anti-thyroglobulin antibodies? Clin Endocrinol 1983; 19: 597-601.

Schneider AB, Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978; 47: 126-37.

Feldt-Rasmussen U, Rasmussen AK. Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. J Endocrinol Invest 1985; 8: 571-6.

Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42: 164-73.

Žarković M. Diagnosis of thyroid disease. Principles and problems. Journal of Medical Biochemistry 2010; 29: 231-36.

Clark PM, Beckett G. Can we measure serum thyroglobulin? Ann Clin Biochem 2002; 39: 196-202.

Stanojević M, Savin S, Cvejić D, Đukić A, Živančević Simonović S. Correlation of thyroglobulin concentrations measured by radioimmunoassay and immunometric assay and the influence of thyroglobulin antibody. J Immunoassay Immunochem 2009; 30: 197-207.

Stanojević M, Savin S, Cvejić D, Djukić A, Jeremić M, Živancević-Simonović S. Comparison of the influence of thyroglobulin antibodies on serum thyroglobulin values from two different immunoassays in post surgical differentiated thyroid carcinoma patients. J Clin Lab Anal 2009; 23: 341-6.

Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3-126.

Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003; 13: 861-5.

Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al. Human thyroglobulin reference material (CRM 457). 2nd part: Physicochemical characterization and certification. Ann Biol Clin (Paris) 1996; 54: 343-8.

Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 1988; 11: 175-81.

Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996; 42: 661-3.

Ferrari L, Biancolini D, Seregni E, Aliberti G, Martinetti A, Villano C, et al. Critical aspects of immunoradiometric thyroglobulin assays. Tumori 2003; 89: 537-9.

Schultz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and tissue-derived thyroglobulin in men. J Clin Invest 1989; 19: 459-63.

Hajduković Lj, Savin S, Čuperlović M, Movsesijan M, Sinadinović J. Karakterizacija 125J-h-tireoglobulina pomoću afinitetne hromatografije na koloni fitohemaglutinin-sefaroze 4B. Med Raz 1988; 27: 27-33.

Savin S, Sofronić LJ, Sinadinović J. Occurrence of antithyroxine antibodies in rabbits immunized with iodine-poor human thyroglobulin. Exp Clin Endocrinol 1990; 95: 375-83.

Feldt-Rasmussen U, Hyltoft Petersen P, Blaabjerg O, Horder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. Acta endocrinol (Copenh) 1980; 95: 328-34.

Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SKG. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003; 88: 3069-74.

Giovanella L, Ghelfo A. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. Clin Chem 2007; 53: 1871-2.

Pacini F, Mariotti S, Formica N, Elisei R. Thyroid auto-antibodies in thyroid cancer: incidence and relationship with tumor outcome. Acta Endocrinol 1988; 119: 373-80.

Spencer CA, Wang C, Fatemi S, Guttler RB, Takeuchi M, Kazarosyan M. Serum Thyroglobulin Autoantibodies: Prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-7.

Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, et al. Disappearance of humoral autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139: 346-51.

Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 1999; 11: 240-4.

Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, et al. Clinical significance of elevated level of serum anti-thyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57: 215-21.

Spencer CA. J Editorial: Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg auto-antibodies. Clin Endocrinol Metab 2004; 89: 3702-4.

Cubero JM, Rodriguez-Espinosa J, Gelpi C, Estorch M, Corcoy R. Thyroglobulin autoantibody levels below the cut-off positivity can interfere with thyroglobulin measurement. Thyroid 2003; 13: 659-61.

Stanojević M, Petrović M, Đukić A, Savin S, Dimitrijević Lj, Živančević-Simonović S. Uticaj antitireoglobulinskih antitela na koncentraciju tireoglobulina izmerenu imunoradiometrijskim testom. Med časopis 2007; 41: 18-19.

Henry M, Malthiery Y, Zanelli E, Charvet B. Epitope mapping of human thyroglobulin: heterogeneous recognition by thyroid pathologic sera. J Immunol 1990; 145: 3692-8.

Savin S, Sinadinović J, Mićić JV, Movsesijan M. Radioimunološka metoda (RIA) za određivanje tireoglobulinskih autoantitela u humanom serumu. Radiol lugoslav 1983; 1: 363-6.

Sinadinović J, Sofronić Lj, Prelević G, Čuperlović K, Savin S. Immunochemical method for determination of thyroglobulin autoantibodies. Periodicum Biologorum 1983; 85: 255-6.

McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid 2004; 14: 510-20.

Thomas D, Liakos V, Vassiliou E, Hatzimarkou F, Tsatsoulis A, Kaldrimes P. Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation. J Endocrinol Invest 2007; 30: 173-80.

Tumino S, Belfore A. Appearance of antithyroglobulin antibodies as the sole sign of metastatic lymph nodes in patients operated on for papillary thyroid cancer: a case report. Thyroid 2000; 10: 431-3.

Feldt-Rasmussen U, Bech K, Date J, Hyltoft Pedersen P, Johansen K, Nistrup Madsen S. Thyroid stimulating antibodies, thyroglobulin antibodies and serum proteins during treatment of Graves disease with radioiodine or propylthiouracil. Allergy 1982; 37: 161-7.

Sapin R, D'Herbomez M, Gasser F, Meyer L, Schlinger JL. Increased sensitivity of a new assay for antithyroglobulin antibody detection in patients with autoimmune thyroid disease. Clin Biochem 2003; 36: 611-16.

Benvenga S, Burek CL, Talor M, Rose NR, Trimarchi F. Heterogeneity of the thyroglobulin epitopes associated with circulating thyroid hormone autoantibodies in Hashimoto's thyroiditis and non-autoimmune thyroid diseases. J Endocrinol Invest 2002; 25: 977-82.

Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992; 33: 1478-80.

Quevedo I, Campino C, Rodríguez Portales JA, Arteaga E, López JM, Campusano C, et al. Anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid cancer: residual or relapsing disease markers? Rev Med Chil 2002; 130: 167-72.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2017: 1.378
5-year IMPACT FACTOR: 0.704



CiteScore 2017: 1.05

SCImago Journal Rank (SJR) 2017: 0.307
Source Normalized Impact per Paper (SNIP) 2017: 0.532

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 278 273 16
PDF Downloads 57 57 6